Market closed
Mersana Therapeutics/$MRSN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Mersana Therapeutics
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Ticker
$MRSN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
123
Website
MRSN Metrics
BasicAdvanced
$331M
Market cap
-
P/E ratio
-$0.61
EPS
1.47
Beta
-
Dividend rate
Price and volume
Market cap
$331M
Beta
1.47
52-week high
$6.28
52-week low
$1.22
Average daily volume
1.3M
Financial strength
Current ratio
2.351
Quick ratio
2.287
Long term debt to equity
1,555.291
Total debt to equity
3,005.338
Interest coverage (TTM)
-11.28%
Management effectiveness
Return on assets (TTM)
-22.97%
Return on equity (TTM)
-280.29%
Valuation
Price to revenue (TTM)
9.371
Price to book
313.93
Price to tangible book (TTM)
313.93
Price to free cash flow (TTM)
-3.416
Growth
Revenue change (TTM)
-14.70%
Earnings per share change (TTM)
-65.43%
3-year revenue growth (CAGR)
832.23%
3-year earnings per share growth (CAGR)
-34.19%
What the Analysts think about MRSN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Mersana Therapeutics stock.
MRSN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MRSN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MRSN News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Mersana Therapeutics stock?
Mersana Therapeutics (MRSN) has a market cap of $331M as of December 12, 2024.
What is the P/E ratio for Mersana Therapeutics stock?
The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of December 12, 2024.
Does Mersana Therapeutics stock pay dividends?
No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Mersana Therapeutics dividend payment date?
Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.
What is the beta indicator for Mersana Therapeutics?
Mersana Therapeutics (MRSN) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.